Insider Selling: Insmed Incorporated (NASDAQ:INSM) CEO Sells $1,461,375.00 in Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $77.94, for a total value of $1,461,375.00. Following the completion of the transaction, the chief executive officer now directly owns 379,534 shares of the company’s stock, valued at approximately $29,580,879.96. The trade was a 4.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

William Lewis also recently made the following trade(s):

• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The stock was sold at an average price of $80.90, for a total transaction of $6,419,415.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The shares were sold at an average price of $70.18, for a total transaction of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The stock was sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total transaction of $1,310,812.50.

Insmed Stock Performance

NASDAQ INSM opened at $79.95 on Friday. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $82.04. The firm has a market capitalization of $14.30 billion, a P/E ratio of -14.41 and a beta of 1.11. The stock’s fifty day moving average is $72.79 and its two-hundred day moving average is $73.10. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on INSM shares. Truist Financial reaffirmed a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday. Morgan Stanley lifted their target price on shares of Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday. Guggenheim upped their price target on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and an average price target of $85.00.

Institutional Investors Weigh In On Insmed

A number of hedge funds have recently modified their holdings of INSM. Steward Partners Investment Advisory LLC raised its stake in Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. V Square Quantitative Management LLC purchased a new stake in shares of Insmed during the 3rd quarter valued at approximately $30,000. GAMMA Investing LLC raised its position in shares of Insmed by 71.3% during the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 224 shares during the period. Spire Wealth Management acquired a new position in shares of Insmed in the 4th quarter valued at $47,000. Finally, Exchange Traded Concepts LLC increased its position in shares of Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares during the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.